JPRN-jRCT2031210139进行中（未招募）1 期
ONO-7913-02: Multi-center, open-label phase 1 study of ONO-7913 (magrolimab) in combination with azacitidine in patients with MDS
Osawa Masahiro0 个研究点目标入组 12 人开始时间: 2021年6月9日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Patients with histological confirmation of MDS defined according to WHO classification, with an IPSS-R risk category of intermediate, high, or very high risk
- •2. Patients judged by the investigator or subinvestigator to be appropriate for treatment with azacitidine
- •3. Patients with ECOG Performance Status of 0 to 1
排除标准
- •1. Patients who are determined to undergo allogeneic hematopoietic stem cell transplantation
- •2. Patients previously treated with azacitidine
- •3. Patients with severe complication
研究者
相似试验
进行中（未招募）
1 期
ONO-7913-04: ONO-7913 Phase 1 StudyJPRN-jRCT2051210038Hirashima Yoshinori60
招募中
1 期
ONO-7914-01:Phase I study of ONO-7914 alone and in combination with ONO-4538 in patients with solid tumorsJPRN-jRCT2031210530Hirashima Yoshinori204
进行中（未招募）
1 期
Clinical trial conducted in two parts: the first (phase I) to find out the safe dose of BIBF 1120 in the treatment of patients with liver cancer and the second part (phase II) to compare this dose of BIBF 1120 with Sorafenib in the treatment of hepatocellular carcinoma (liver cancer)Histologically or cytologically confirmed hepatocellular carcinoma not amenable to local therapy with adequate renal, hematological and liver paramenters with Child-Pugh score 5-6, in 1st line systemic therapy.EUCTR2009-011925-14-ATBoehringer Ingelheim RCV GmbH & Co. KG132
进行中（未招募）
1 期
Clinical trial conducted in two parts: the first (phase I) to find out the safe dose of BIBF 1120 in the treatment of patients with liver cancer and the second part (phase II) to compare this dose of BIBF 1120 with Sorafenib in the treatment of hepatocellular carcinoma (liver cancer)EUCTR2009-011925-14-DEBoehringer Ingelheim Pharma GmbH & Co. KG132
进行中（未招募）
1 期
Clinical trial conducted in two parts: the first (phase I) to find out the safe dose of BIBF 1120 in the treatment of patients with liver cancer and the second part (phase II) to compare this dose of BIBF 1120 with Sorafenib in the treatment of hepatocellular carcinoma (liver cancer)EUCTR2009-011925-14-NLBoehringer Ingelheim bv132